Carl L. Gordon has served as a member of our board of directors since March 2020 and previously served as Chair of our board of directors from April 2023 through June 2024. Since 1995 Dr. Gordon has been a member of OrbiMed Advisors LLC, an investment firm where he is a Founding Partner and Co-Head of Global Private Equity. Dr. Gordon currently serves on the board of directors of Adicet Bio, Inc., ArriVent Biopharma, Inc., Compass Therapeutics Inc., and Terns Pharmaceuticals, Inc., as well as several private companies. Dr. Gordon previously served on the board of directors of several companies, including Arsanis, Inc. (which merged with X4 Pharmaceuticals, Inc.), Alector, Inc., Gemini Therapeutics Inc. (which merged with Disc Medicine, Inc.), Kinnate Biopharma, Inc., ORIC Pharmaceuticals, Inc., Passage Bio Inc., Prevail Therapeutics Inc., SpringWorks Therapeutics Inc., Theseus Pharmaceuticals, Inc. and Turning Point Therapeutics, Inc. Prior to OrbiMed, Dr. Gordon received a B.A. in Chemistry from Harvard College, a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and was a Fellow at The Rockefeller University.
What is Carl L. Gordon's net worth?
The estimated net worth of Carl L. Gordon is at least $64.66 million as of February 14th, 2025. Gordon owns 3,205,930 shares of Keros Therapeutics stock worth more than $64,663,608 as of December 4th. This net worth estimate does not reflect any other assets that Gordon may own. Learn More about Carl L. Gordon's net worth.
How do I contact Carl L. Gordon?
Has Carl L. Gordon been buying or selling shares of Keros Therapeutics?
Carl L. Gordon has not been actively trading shares of Keros Therapeutics over the course of the past ninety days. Most recently, Carl L. Gordon sold 250,000 shares of the business's stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a transaction totalling $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares of the company's stock, valued at $5,260,163.22. Learn More on Carl L. Gordon's trading history.
Who are Keros Therapeutics' active insiders?
Are insiders buying or selling shares of Keros Therapeutics?
During the last year, Keros Therapeutics insiders bought shares 1 times. They purchased a total of 934,258 shares worth more than $9,464,033.54. During the last year, insiders at the sold shares 2 times. They sold a total of 10,176,595 shares worth more than $180,634,561.25. The most recent insider tranaction occured on October, 15th when Major Shareholder Adar1 Capital Management, Llc sold 5,389,264 shares worth more than $95,659,436.00. Insiders at Keros Therapeutics own 20.6% of the company.
Learn More about insider trades at Keros Therapeutics. Information on this page was last updated on 10/15/2025.
